Riho Klement
7 Papers
Riho Klement is an academic researcher. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.
Avraham Karasik,Stefanie Lanzinger,Elise Chia-Hui Tan,Daisuke Yabe,Dae Jung Kim,Wayne H-H Sheu,Cheli Melzer-Cohen,Reinhard W. Holl,Kyoung Hwa Ha,Kamlesh Khunti,Francesco Zaccardi,Anuradha Subramanian,Krishnarajah Nirantharakumar,Thomas Nyström,Leo Niskanen,Majken K. Jensen,Fabian Hoti,Riho Klement,Anouk Deruaz-Luyet,Moe H. Kyaw,Lisette Koeneman,Dorte Vistisen,Bendix Carstensen,Sigrun Halvorsen,Gisle Langslet,Soulmaz Fazeli Farsani,Elisabetta Patorno,Julio Núñez +27 more
TL;DR: The EMPRISE Europe and Asia study as discussed by the authors is a non-interventional cohort study using data from 2014-2019 in seven European (Denmark, Finland, Germany, Norway, Spain, Sweden, United Kingdom) and four Asian (Israel, Japan, South Korea, Taiwan) countries.
18
Pulmonary arterial hypertension associated with congenital heart disease: real-world analysis of clinical characteristics, treatment patterns and outcomes from EXPOSURE
TL;DR: Clinical characteristics, treatment patterns, hospitalisation and mortality are described for PAH-CHD patients classified into four clinical subgroups and most ES patients remained on the same treatment regimen 6 months after baseline, with limited treatment escalation.
Characterisation of pulmonary arterial hypertension patients with cardiovascular comorbidities treated with selexipag: real-world evidence from the EXPOSURE study
TL;DR: Real-world data from Europe and Canada suggest that more than 50% of patients who initiated selexipag had ≥1 cardiovascular comorbidity, whereas in the real world, patients withComorbidities had more severe functional impairment vs those without.